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Abstract
Background:  Ocular melanoma is the leading intraocular malignancy. There is no effective
treatment for metastatic ocular melanoma. We sought a treatment targeting the tumor
microenvironment as well as the tumor cells.
Methods: Migration of HUVEC cells, the ability of HUVEC cells to form tubes, and proliferative
capacity of a human ocular melanoma cell line were tested in the presence of lenalidomide and
sorafenib alone and in combination. The compounds were also tested in a rat aortic ring assay and
were tested in a highly aggressive human ocular melanoma xenograft model.
Results: Lenalidomide and Sorafenib inhibit HUVEC ability to migrate and form tubes and when
used in combination the inhibition is increased. The agents alone and in combination inhibit
outgrowth in the rat aortic ring model. The combination of the agents improved the inhibition over
either single agent. In a xenograft model, combination therapy inhibited tumor growth over
inhibition by single agent alone in a significant fashion (p < 0.004: lenalidomide and p < 0.0035:
sorafenib). Furthermore, spontaneous lung metastasis development was completely inhibited in the
combination treated animals. Sixty percent of vehicle treated animals developed lung metastases
compared to 50% of lenalidomide treated animals, and 33% of sorafenib treated animals.
Conclusion: Lenalidomide and sorafenib are effective at targeting endothelial cells, inhibiting
growth of ocular melanoma cells and can inhibit growth of tumors in a xenograft model as well as
inhibit development of metastases. Combining these agents works in an additive to synergistic way
to inhibit the growth of tumors and development of metastases.
Background
Although ocular melanoma (OM) is a relatively rare diag-
nosis, it is the leading intraocular malignancy and
accounts for approximately 5% of all melanomas. It has a
slight male predominance and the age-specific incidence
peaks at 70 years of age[1]. Patients can expect a 21–55%
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chance of developing metastatic disease within 10 years,
depending on the size of the primary lesion. For patients
who develop metastatic disease, the median survival is <
6 months and virtually all of them will succumb to their
cancer. Although OM is known for its metastatic tropism
to the liver (89%), it can also be found in a number of
other locations, including lung (29%), bone (17%), skin
or subcutaneous tissue (12%), lymph node (11%), brain
(5%), and other tissues (> 20%)[2]. These sites of disease
are not mutually exclusive and they underscore OM's
behavior as a systemic disease. Although some regional
therapies have modest efficacy in treating hepatic tumor
burden, their limitation has remained regional and distant
recurrence[3,4]. Systemic therapy has unfortunately been
ineffective. Aggressive tumor histologies like OM are
likely to circumvent cytotoxic therapies, because the only
target is cell death. Our approach is to target the tumor
microenvironment using agents which have a broad spec-
trum activity of against the tumor and its vasculature.
Sorafenib (Nexavar™, Bayer), recently approved for the
treatment of metastatic renal cell carcinoma, is a bi-aryl
urea shown to inhibit multiple receptor tyrosine kinases
(RTK) and Ser/Thr kinases[5]. These include but are not
limited to: all isoforms of Raf, all isoforms of VEGFR, and
PDGFR-β. This multifunctional profile lends itself to inhi-
bition of: tumor and endothelial cell proliferation via the
Ras/Raf/MEK pathway, endothelial cell activation and
proliferation via VEGFR-2, recruitment of pericytes via
PDGFR-β (required for vessel stabilization and maturity),
recruitment of stabilizing stromal cells to the tumor's
parenchyma, as well as subsequent stimulation of stromal
cell derived growth factors [5-10].
Lenalidomide (Revlimid®Celgene) is one of the IMiDs®
compounds that modulate the immune system and other
biologically important targets through multiple mecha-
nisms of action[11]. It is a thalidomide analog approved
for the treatment of multiple myeloma and other similar
lymphoproliferative diseases. It also has a multifunctional
profile and has been shown to cause caspase-dependent
apoptosis of tumor cell lines [12,13], inhibit bFGF and
tumor induced neovascularization in vivo [14,15], abro-
gate AKT/PKB phosphorylation required for endothelial
cell migration[14] and tumor cell proliferation[16],,
inhibit proangiogenic TNF-α production[17], and activate
and stimulate proliferation of cytotoxic T-cell lym-
phocytes[18].
The combination of these two compounds addresses the
tumor microenvironment as it pertains to tumor cell pro-
liferation and apoptosis, vascular induction and stabiliza-
tion, immunomodulation, and stromal support. Our
hypothesis is that modulation of the tumor's microenvi-
ronment with multi-directed therapy, in the form of com-
binatory treatment with sorafenib and lenalidomide, will
have improved efficacy in angiogenesis assays and a
human ocular melanoma xenograft model. We therefore
studied these agents alone and in combination, in our in
vitro, ex vivo and in vivo models. Our goal is to develop
more effective agents for the treatment of patients with
stage IV OM.
Methods
Compound preparation
Sorafenib (Bayer) was obtained from the NIH Pharmacy
in the commercially available form of 200 mg tablets.
Total pill weight is 350 mg and an index of 1.75 was used
to keep the molarity in terms of active ingredient (MW-
637 g/mol). Tablets were pulverized with a mortar and
pestle and kept from light in a dessicator. Lenalidomide
(MW-259.3 g/mol) was obtained from Celgene Corpora-
tion. For in vitro and ex vivo studies lenalidomide, soraf-
enib, oxaliplatin and fumagillin (Sigma-F6771) were
solubilized in 100% DMSO on the day of treatment.
Oxaliplatin was used as a positive control in these experi-
ments due to its known inhibition of ocular melanoma
cells in vitro and fumagillin was used as a positive control
secondary to its known inhibition of endothelial cells in
vitro. For combinatory treatments, the compounds were
kept in 1:1 concentration ratios when solubilized in
DMSO, so that the final treatment media kept a final uni-
formity of 0.1% DMSO. For in vivo studies, sorafenib
and/or lenalidomide were suspended in an aqueous solu-
tion of 0.5% carboxymethylcellulose and 0.25% Tween
80 (Sigma-C9481 and P8074) immediately prior to
cohort gavage.
Angiogenesis assays
Migration assay
The outside undersurfaces of twelve well plates were
scribed with a Sharpie permanent marker, so that each
well was marked at its largest diameter. Human umbilical
vein endothelial cells (HUVEC, ATCC CRL-1730) were
then plated in EGM (Cambrex-cc3162) and allowed to
reach confluence. After HUVEC reached confluence, EGM
was aspirated and cells were washed by submersion and
gentle agitation in sterile 37°C PBS without Ca++ and
Mg++. A wound in the monolayer was made perpendicu-
lar to the scribed line using a P1000 pipette tip. The plate
was then washed again by submersion and treatment
media was added. Treatment media consisted of EGM-2
(Cambrex-cc3156) with 1% FBS and different concentra-
tions of experimental compound. All groups were kept in
a 37°C incubator. Negative control was 0.1% DMSO and
when this group reached virtual confluence (~20–24
hours), all plates were fixed with 4% formalin and stained
with DAPI. Plates were then imaged with a fluorescent
inverted phase contrast microscope (Zeiss). The high
power field immediately above and below the scribed lineJournal of Translational Medicine 2007, 5:38 http://www.translational-medicine.com/content/5/1/38
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were prospectively designated for analysis, allowing six
images per treatment group (Axiovision software). A base-
line cohort was fixed, stained and imaged immediately
after monolayer wounding. All images were left in their
original size format. Quantization was blinded and per-
formed by creating a longitudinal axis over the area of
minimal density that corresponded to the site of wound
formation. The average baseline wound area was centered
over the axis and all cells that were present with in that
area were assumed to have migrated there. These cells
were counted and the cell counts constituted raw data for
analysis.
Tube formation assay
Matrigel (BD Biosciences-354234) was plated at 200 ul/
well in 24 well plates and allowed to reach the solid phase
after one hour in a 37°C incubator. HUVEC were then
suspended in treatment media identical to the migration
assay and plated on top of the Matrigel at a density of 50,
000 cells per well. After six hours in an incubator, the
wells were imaged on an inverted phase contrast micro-
scope (Zeiss, Axiovision). These images were used to
derive data. HUVEC normally form a branching plexus of
tubes on artificial extracellular matrices, such as Matrigel.
Quantization was blinded and performed by counting
each nodal branch point that had 3 or more branches.
Branch point counts per image constituted the raw data
for statistical analysis. There were four images per treat-
ment group.
Rat aortic ring assay
Matrigel was plated at 250 ul/chamber on CultureSlides
(BD 354104) and allowed to solidify overnight at 37°C.
Next, six week old Sprague-Dawley rats were sacrificed
and their thoracoabdominal aortas procured. The aortas
were dissected free of any fibro-adipose tissue and sec-
tioned into 0.5 mm rings. The rings were kept in EGM-2
media in a 50 ml conical tube while other animals (total
of four) were being processed. Gentle agitation of the con-
ical tube constituted randomization of any one animal's
contribution to a particular treatment group. All rings that
had branches or were eccentric were removed. Rings were
then placed on the Matrigel layer, one ring per chamber.
Each ring was then embedded in Matrigel by the addition
of another 200 ul. These were allowed to incubate for one
hour at 37°C and EGM-2 media was added. The rings
were incubated for another 24 hours and the next day
media was exchanged for basal media containing various
concentrations of drug and 0.1% DMSO. The rings were
incubated in treatment media for five days, with media
and drug compound being refreshed every other day, after
five days they were imaged on an inverted phase contrast
microscope (Zeiss). All images were acquired (Axiovision)
via the same settings and in the same sitting. The images
were imported into Adobe Photoshop CS2 and were not
modified in size, shape or contrast, in any way. Blinded
quantization was done using Photoshop's magic wand
function to select the pixel densities associated with the
vascular sprouts of each ring. Cutting and pasting allowed
confirmation that all and only sprouts were selected; the
aortic ring itself was excluded. Photoshop's expanded his-
togram was then used to yield pixel counts that repre-
sented the selection. These pixel counts served as raw data
for analysis.
Real-time cell electronic sensing
92.1 cells were grown to subconfluence in RPMI 1640
with 10% FBS. The monolayer was trypsinized, counted
(trypan blue exclusion), and resuspended in complete
media at a density of 1 × 105 cells/ml. The ACEA RT-CES
16× E-Plate Station (ACEA Biosciences, San Diego, CA)
was used in an incubator at 37°C and 5% CO2. 100 ul of
complete RPMI 1640 was added to the wells of 16× E-
Plates (ACEA Biosciences) after which they were allowed
to acclimate in the incubator for 30 minutes. ACEA RT-
CES SP software (ACEA Biosciences) was then used to cal-
ibrate the plates. 100 ul of cell suspension was added to
the plates and the next day treatment with compound in
DMSO was added to the wells, so that the final concentra-
tion of DMSO was uniformly 0.1%.
Human ocular melanoma xenograft model
All animal studies were in accord with the National Insti-
tutes of Health-Animal Care and Use Committee guide-
lines. Female NCr-nu/nu  mice (Taconic Farms, NCI,
Animal Production Program, Frederick, Maryland) were
used for all tumor challenge experiments. The ocular
melanoma cell line 92.1 (gifted by Bruce R. Ksander, Har-
vard Medical School) was maintained in culture using
RPMI-1640 with 10% FBS. Cells were trypsinized while in
their log growth phase, resuspended in 50% Matrigel and
50% complete RPMI, to a volume that provided a final
cell density of 1 × 108 cells/ml. Mice were then dorsally
injected subcutaneously with 100 ul of cell suspension,
using a 27 g needle. When lesions showed evidence of
progression (~10–14 d), they were randomized to treat-
ment groups. Therapy involved daily oral gavage of 100
mg/kg lenalidomide and/or 60 mg/kg sorafenib in 50 ul
doses through a 22 g oral gavage needle. Subcutaneous
lesions were measured in three dimensions on a MWF
schedule. Tumor volumes [0.52(L × W × H)] constituted
the raw data for analysis. After 14 days of treatment, ani-
mals were euthanized and their subcutaneous lesions
were resected and immediately snap frozen in liquid
nitrogen. In order to count visceral surface lung metas-
tases, the tracheobronchopulmonary tree was resected en
bloc and the trachea was cannulated with a 21 g needle
and insufflated with 10% formalin. The specimens were
then stored in formalin overnight and the next day, theJournal of Translational Medicine 2007, 5:38 http://www.translational-medicine.com/content/5/1/38
Page 4 of 9
(page number not for citation purposes)
counts were blindly performed with the use of 2× surgical
loupes and a dissecting microscope.
Statistical method
Statistical analysis was performed with the use of Graph-
Pad InStat v.3.05, GraphPad Prism v.4.02, and Excel
2002. Statistical analysis of the migration and tube forma-
tion assay data involved One-way ANOVA followed by
Tukey-Kramer multiple comparisons testing. The rat aor-
tic ring data underwent One-way ANOVA followed by
Tukey-Kramer multiple comparisons testing if assump-
tion testing by Bartlett's method revealed no differences in
the standard deviations between groups. If there was a dis-
parity in inter-group standard deviations, then the non-
parametric Kruskal-Wallis test was used, followed by
Dunn's multiple comparisons method. Relationships of
significance were then applied to unpaired Student's T test
with Bonferroni adjustment for final p values. Data from
the xenograft model were evaluated with One-way
ANOVA with multiple comparisons testing. This also was
then applied to unpaired Student's T test with Bonferroni
adjustment for final p values. The xenograft outcomes
analysis was made on the basis of given measurement
days.
Results
Lenalidomide
Migration assay
Endothelial cells in monolayer normally migrate toward
regions of lower population density. Migration, together
with proliferation lends itself to uniformity of density. We
used the migration assay with HUVEC, to see if endothe-
lial cells sustained a functional deficit in motility when
subject to lenalidomide. By making a wound in a conflu-
ent monolayer of HUVEC and subjecting the cells to basal
treatment media, we minimized the level of proliferation
and were able to blindly quantitate the cellular migration
capacities and how they were affected by our treatments
(Fig. 1A). Inhibition was statistically evident at all tested
concentrations of lenalidomide. The 0.01 μM group
exhibited the maximum inhibition (67%), p < 0.002.
Tube formation assay
Human endothelial cells normally form tubes and
branching networks when cultured in the presence of a
three dimensional supportive matrix. We evaluated
whether their ability to fulfill this role was affected by the
presence of lenalidomide, by resuspending HUVEC in
treatment media and plating them on Matrigel. HUVEC's
ability to form branching tubes was significantly reduced
(Fig. 1B). The maximum inhibition occurred at 0.001 μM
(73%) p < 0.0005.
Human ocular melanoma xenograft model
Our ultimate goal is to evaluate compounds for the treat-
ment of patients with ocular melanoma. In order to do
this, we developed a xenograft model from a human ocu-
lar melanoma cell line, and evaluated lenalidomide's abil-
ity to mitigate tumor growth and lung metastases. The
primary endpoints were mean tumor volume and pres-
ence or absence of visceral surface lung metastases after a
fourteen day treatment regimen (Fig 2C and 2D). Lenalid-
omide treated mice exhibited delayed tumor growth (p <
0.0001), which by day fourteen exhibited a 52% relative
reduction in mean tumor volumes. After sacrifice of the
animals the lungs were blindly evaluated for number of
visceral surface metastases. All animals developed lung
metastases of which the control group developed a
median of 26.5 lung lesions per animal (CI = 17.57–
33.76) and the treatment group developed a median of 12
lung lesions per animal (CI = 10.38–16.20, p = 0.0047).
Lenalidomide and sorafenib
Anti-vascular assays
Results of the migration assay showed that inhibition of
migration was statistically evident for all tested concentra-
tions of all treatments (Fig. 1A). Sorafenib and lenalido-
mide were equivalent, except at the 1 μM concentration,
where sorafenib displayed more anti-migration activity (p
= 0.0015). In the 0.001 μM cohort, the combinatory arm
showed greater inhibition of migration than lenalido-
mide (p < 0.05) or sorafenib (p < 0.01) alone. Tube for-
mation and branching capabilities were also stunted by all
treatment groups at all concentrations (Fig. 1B). Although
sorafenib exhibits more inhibition than lenalidomide,
combinatory treatment was more inhibitive than either
single treatment group at the 0.001 μM (p < 0.05) and
0.01 μM (p < 0.05) concentrations. We then sought to test
whether the compounds had any effect on the develop-
ment of neovasculature from a mature preexisting artery.
To test this we used the rat aortic ring assay (Fig. 1C).
Lenalidomide showed significant inhibition at all concen-
trations tested and sorafenib showed significant inhibi-
tion at and above the 0.01 μM concentration;
lenalidomide was statistically more effective at lower
doses. The combinatory treatments were significantly
effective at inhibiting neovascular outgrowth at all con-
centrations, and were significantly more inhibitive than
treatment with lenalidomide alone at the 0.01 μM (p =
0.001) and 0.1 μM (p = 0.005) and sorafenib alone at the
0.01 μM (p = 0.0005) and 0.1 μM (p = 0.0015) doses.
Anti-tumor assays
Real-time cell electronic sensing
After noting the anti-vascular activity of combinatory
treatment and given the known biologic targets of lenalid-
omide and sorafenib, we evaluated whether there was a
similar effect on the proliferative potential of a humanJournal of Translational Medicine 2007, 5:38 http://www.translational-medicine.com/content/5/1/38
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(A) Migration assay data for single agent lenalidomide, sorafenib and combination treated HUVEC reveals a dose response  curve that has significant inhibition at all concentrations Figure 1
(A) Migration assay data for single agent lenalidomide, sorafenib and combination treated HUVEC reveals a dose response 
curve that has significant inhibition at all concentrations. Treatment of HUVEC with a 1:1 combination of lenalidomide and sor-
afenib showed superior inhibitive efficacy than monotherapy with either compound. There was no detectable difference 
between lenalidomide or sorafenib monotherapy for the migration assay. Each experimental condition was repeated six times. 
(B) Tube formation assay showed inhibition of HUVEC ability to form tubes with a maximal inhibition with lenalidomide treat-
ment at 0.001 uM (p = 0.005). The tube formation capabilities of HUVEC were more profoundly inhibited by sorafenib than 
lenalidomide at all tested concentrations. The combination of compounds showed superior inhibitory efficacy at all concentra-
tions. Each experimental condition was repeated four times. (C) Lenalidomide inhibited the rat aortic ring assay more effec-
tively at lower concentrations than did sorafenib, and its inhibition was present at across all concentrations. Combination 
treatment with both compounds was more effective at all evaluable concentrations. Images are representative of those used 
for data derivation. Each experimental condition was repeated eight times.Journal of Translational Medicine 2007, 5:38 http://www.translational-medicine.com/content/5/1/38
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ocular melanoma cell line. The 92.1 cell line was used in
order to make correlations with xenograft data. RT-CES of
the 92.1 cell line provided a reproducible dynamic evalu-
ation of cell population growth curves. Analysis of this
data revealed growth kinetics of 92.1 in the presence of
different compounds at different concentrations (Fig. 2A
Evaluation of 92.1's proliferative potential was done with RT-CES (A and B) Figure 2
Evaluation of 92.1's proliferative potential was done with RT-CES (A and B). Each experimental condition was repeated eight 
times. This technology yielded kinetic growth data which showed combination treatment with lenalidomide and sorafenib (1:1) 
to have an anti-proliferative effect, which is first apparent at 0.001 μM and most profoundly independent from either single 
agent's effect at 0.01 μM (A). Lenalidomide alone showed no appreciable activity against proliferation regardless of concentra-
tion. Sorafenib alone exhibited anti-proliferative activity which was initially evident at 0.1 μM (B), 10–100× more concentrate 
than when a similar effect is produced by combination therapy. When therapy was evaluated with the xenograft model, the 
combination treatment cohort showed the most tumor growth delay Each treatment group represents eight animals. (C). 
Lenalidomide and sorafenib both displayed tumor growth stasis which was significantly different from carrier treated animals 
and equivocal from each other. Combinatory therapy showed significant growth retardation relative to either monotherapy. 
This pattern of anti-tumor efficacy was also seen in the analysis of metastatic frequency. Each treatment group represents eight 
animals (D).
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and 2B). Lenalidomide displayed no appreciable effect on
cell index (a dimensionless unit which is proportional to
the actual cell number and is a surrogate index of net pro-
liferation and apoptosis[19]). Sorafenib exhibits an anti-
proliferative dose response, which first becomes evident at
0.1 μM and becomes more profound with increasing con-
centration. Combination (1:1) treatment of 92.1 cells
resulted in a dose response that is initially evident at 0.001
μM, but is most profoundly differential from individual
monotherapies at 0.01 μM. By adding lenalidomide, in
the form of combination treatment, the sorafenib dose
response is transposed to the left by one to two orders of
magnitude concentration.
Xenograft
After we found potentiated anti-vascular activity, as well
as anti-proliferative activity in the tumor cell line, we
wanted to investigate whether there was an increase in
anti-tumor activity in vivo, relative to monotherapy. In
order to do this, we used our human ocular melanoma
xenograft model with the priory endpoint of mean tumor
volume after fourteen days of treatment (Fig. 2C). Second-
arily, we looked at time to significant tumor growth delay
and frequency of lung metastasis (Fig. 2D). The combina-
tion treatment group showed improved tumor growth sta-
sis relative to lenalidomide (p = 0.004) and sorafenib (p =
0.0035) at day 14. Inhibition of tumor growth relative to
carrier treated animals, was statistically evident by day 7
for lenalidomide (p = 0.0185), sorafenib (p = 0.027) and
combination (p = 0.0005) treatment cohorts. Combina-
tion therapy was associated with significantly lower mean
tumor volumes than sorafenib by day 7 (p = 0.005) and
lenalidomide by day 12 (p = 0.003). Visceral pulmonary
surface metastases were evident in 66% of carrier treated,
50% of lenalidomide treated, 33% of sorafenib treated,
and 0% of combination therapy treated animals. Mice
were followed for weight gain or loss, body temperature
changes, skin changes as well as for behavioral changes
such as restlessness or aggression. There was no evidence
of any treatment related toxicity in mice treated with lena-
lidomide alone, sorafenib alone or the combination of
the two agents.
Discussion
Historically, the efficacy of chemotherapy has been based
on how well it could inhibit the growth of tumor cells.
More recently, the tumor microenvironment has been
shown to play a vital role in the spread of a primary tumor
as well as a tumor's ability to metastasize. The tumor
microenvironment is made up of a complex network of
tumor, endothelial, lymphatic and fibroblast cells on an
extracellular matrix. These cells all have a role in the
growth of the tumor and as such agents must target mul-
tiple aspects of the microenvironment to be effective.
Our lab has tested two agents which target different path-
ways and different cell types in the tumor microenviron-
ment. We have shown that lenalidomide is able to inhibit
the function of endothelial cells in in vitro assays. Lenal-
idomide inhibits endothelial cells from creating tubes and
also inhibits endothelial cells from migrating but does not
have a direct cytotoxic effect on the endothelial cells. Fur-
thermore, in an ex vivo assay testing how the compound
affects the entire tumor microenvironment, lenalidomide
inhibits the outgrowth of buds from the rat aortic ring.
These observations of inhibition of endothelial tubule
formation and migration, as well as inhibition of micro-
vessel sprouting in the rat aortic ring model, along with a
lack of an effect on endothelial cell proliferation, are con-
sistent with previous reports on the activity of lenalido-
mide. [14,15] In our experience, the rat aortic ring is one
of the best predictors of how an agent will affect tumors in
vivo because it functions as a microcosm of the tumor
microenvironment. In a highly aggressive in vivo model
of a human ocular melanoma, lenalidomide alone was
able to slow the growth of subcutaneous tumors grown in
the mouse, as well as reduce the number of lung metas-
tases.
Although lenalidomide had an anti-angiogenic effect in
several in vitro, and ex vivo assays, and an effect on in vivo
tumors, we wanted to improve on the effect by adding a
compound to target additional pathways which lenalido-
mide might not inhibit and thus disrupt more pathways
in the complex tumor microenvironment. In addition, the
combination may decrease the ability of the tumor to
escape the effects of a single agent by compensatory mech-
anisms we chose sorafenib, based on its ability to block
several of the receptors responsible for endothelial cell
growth and function: namely VEGFR, and PDGFR-beta.
Furthermore, sorafenib is able to block the Ras kinase
pathway which has been shown to be active in melanoma
tumor cells. This combination of a Ras/MAPK pathway
inhibitor in combination with lenalidomide, which has
been shown to interfere with AKT signaling in endothelial
cells[14] and tumor cells[16], is perhaps advantageous
because it simultaneously blocks signaling through both
the MAPK and AKT pathways. As suspected, the addition
of sorafenib improved the inhibition of endothelial cell
function in vitro as well as enhanced the inhibition of
cells which make up the microenvironment as shown in
the rat aortic ring model. Sorafenib was also shown to
have a direct cytotoxic effect on our human ocular
melanoma cell line in an assay of cell proliferation. The
agents were able to slow the growth of tumors without
causing toxicity to the mice and with combination treat-
ment there was no added toxicity. Most importantly, in a
highly aggressive in vivo model of human ocular
melanoma, the combination of lenalidomide and soraf-
enib was able to inhibit the growth of subcutaneousJournal of Translational Medicine 2007, 5:38 http://www.translational-medicine.com/content/5/1/38
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tumors as well as inhibit the growth of metastatic deposits
in the lungs more effectively than shown by either com-
pound itself.
Conclusion
Lenalidomide is an IMiD which can inhibit the function
of endothelial cells in vitro, can block the outgrowth of
cells from a rat aortic ring mimicking the inhibition of
cells in the tumor microenvironment, and can inhibit the
growth of a primary tumor as well as inhibit the growth of
metastases in a human ocular melanoma xenograft
model. Sorafenib likewise can inhibit endothelial cells in
vitro, ex vivo and can inhibit tumor growth in vivo. Fur-
ther, the combination of lenalidomide and a tyrosine
kinase inhibitor like sorafenib is a viable combination
which targets multiple aspects of the tumor microenviron-
ment in vitro, ex vivo and in vivo. Based on our pre-clini-
cal results, we believe that this combination and this
strategy warrant testing in a clinical setting against ocular
melanoma.
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